Bruce E. Sands, MD, MS; Thomas A. Ullman, MD
Jointly provided by Postgraduate Institute for Medicine and Integritas Communications.
This activity has been supported by independent educational grant from Gilead Sciences, Inc.
Bruce E. Sands, MD, MS
Dr. Burrill B. Crohn Professor of Medicine
Icahn School of Medicine at Mount Sinai
Chief, Dr. Henry D. Janowitz Division of Gastroenterology
Mount Sinai St. Luke’s and Mount Sinai Hospital
New York, New York
Thomas A. Ullman, MD
Professor, Department of Medicine
Albert Einstein College of Medicine
Chief, Division of Gastroenterology
Montefiore Medical Center
Bronx, New York
This activity is intended for clinical gastroenterologists engaged in the care of patients with inflammatory bowel disease (IBD).
After completing this activity, the participant should be better able to:
- Describe targets of current and emerging treatments for IBD in the context of disease pathogenesis
Physicians need further education to fully understand and implement current advanced therapies and distinguish the pathways of disease and targets addressed by newer therapies. This educational activity will provide key clinical data on new and emerging treatments, focusing on the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway in the context of evolving understanding of disease immunopathogenesis.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Integritas Communications. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest:
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.
Bruce E. Sands, MD, MS: Consulting fees: AbbVie Inc., Allergan, Inc., Amgen Inc., Arena Pharmaceuticals, Inc., AstraZeneca plc, Boehringer Ingelheim, Capella BioScience Ltd., Eli Lilly and Company, F. Hoffmann-La Roche AG, Ironwood Pharmaceuticals, Inc., Janssen Scientific Affairs, LLC, Janssen-Cilag, S.A., Otsuka America Pharmaceutical, Inc., Pfizer Canada Inc., Pfizer Inc., Progenity, Inc., Prometheus Laboratories Inc., Protagonist Therapeutics, Inc., Rheos Medicines, Inc., Salix Pharmaceuticals, Inc., Shire plc, Sienna Biopharmaceuticals, Inc., Takeda Pharmaceuticals USA Inc., TARGET PharmaSolutions, Inc., Theravance Biopharma, Inc., Vivelix Pharmaceuticals, Ltd. Honoraria: Gilead Sciences, Inc.
Thomas Ullman, MD: Consulting fees: Pfizer Inc.
Planners and Managers
The PIM planners and managers have nothing to disclose. The Integritas Communications planners and managers have nothing to disclose.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Instructions to Receive Credit
In order to receive credit for this activity, the participant must receive a minimum score of 70% on the posttest and complete the evaluation.
Minimum Hardware/Software Requirements
- Valid email address
- Broadband internet connection
- Computer, smartphone, or tablet running a recent release of a web browser such as Google Chrome, Mozilla Firefox, Apple Safari, or Microsoft Internet Explorer
- Multimedia playback capability, including speakers or headphones
CME Questions - PIM Contact Information
For information about the accreditation of this program, please contact PIM via e-mail at firstname.lastname@example.org or by visiting www.pimed.com.
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
Click "Begin Activity" to acknowledge that you have reviewed the preamble information for this activity.Begin Activity
credit amount 0.25
credit type AMA PRA
Appraising the Therapeutic Armamentarium in Moderate and Severe Disease